Ascletis Announces Entering into a Supply Agreement of Ritonavir Tablets with Simcere

HANGZHOU and SHAOXING,China,Jan. 17,2023 -- Ascletis Pharma Inc. (HKEX: 1672,"Ascletis") today announces that its wholly owned subsidiary Ascletis Pharmaceuticals Co.,Ltd. has entered into a supply agreement of ritonavir tablets with Hainan Simcere Pharmaceutical Co.,Ltd.,a subsidiary of Simcere Pharmaceutical Group Limited (HKEX: 2096,"Simcere").

Ritonavir tablet is a pharmacokinetic booster of multiple oral antiviral protease inhibitors. Ascletis currently owns the only authorized ritonavir oral tablet in China,which has passed bioequivalence study.

About Ascletis

Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK),covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record,Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases,non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution,Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date,Ascletis has three marketed products,i.e. ritonavir tablets,GANOVO® and ASCLEVIR®,and 22 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure),ASC10 and ASC11(oral small molecules for COVID-19 treatment),ASC40 (recurrent glioblastoma),ASC42 (PBC,primary biliary cholangitis),and ASC40 (acne).

For more information,please visit www.ascletis.com.